Ultragenyx Pharmaceutical (RARE) Non Operating Income (2013 - 2017)

Ultragenyx Pharmaceutical (RARE) has reported Non Operating Income for 5 consecutive years, with $4.5 million the latest figure, recorded in Q3 2017.

• In Q3 2017, Non Operating Income rose 412.56% year-over-year to $4.5 million; the TTM figure through Sep 2017 stood at $11.0 million (up 189.18% YoY), while the FY2016 annual figure was $2.2 million, up 2.26% from the prior year.
• Non Operating Income retreated to $4.5 million in Q3 2017 per RARE's latest filing, from $5.6 million in the prior quarter.
• Across five years, Non Operating Income topped out at $5.6 million in Q2 2017 and bottomed at -$3.3 million in Q1 2014.
• Historically, Non Operating Income has averaged $619000.0 across 5 years, with a median of $355000.0 in 2015.
• Annual changes were most pronounced in 2015 — Non Operating Income jumped 5128.57% — and 2016, when it plunged 174.95%.
• Ultragenyx Pharmaceutical's Non Operating Income stood at -$1.8 million in 2013, then surged by 111.44% to $205000.0 in 2014, then surged by 357.56% to $938000.0 in 2015, then sank by 174.95% to -$703000.0 in 2016, then surged by 738.69% to $4.5 million in 2017.
• Business Quant data shows RARE's Non Operating Income at $4.5 million in Q3 2017, $5.6 million in Q2 2017, and $1.7 million in Q1 2017.